Literature DB >> 24018052

Therapeutic potential of fecal microbiota transplantation.

Loek P Smits1, Kristien E C Bouter, Willem M de Vos, Thomas J Borody, Max Nieuwdorp.   

Abstract

There has been growing interest in the use of fecal microbiota for the treatment of patients with chronic gastrointestinal infections and inflammatory bowel diseases. Lately, there has also been interest in its therapeutic potential for cardiometabolic, autoimmune, and other extraintestinal conditions that were not previously considered to be associated with the intestinal microbiota. Although it is not clear if changes in the microbiota cause these conditions, we review the most current and best methods for performing fecal microbiota transplantation and summarize clinical observations that have implicated the intestinal microbiota in various diseases. We also discuss case reports of fecal microbiota transplantations for different disorders, including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, insulin resistance, multiple sclerosis, and idiopathic thrombocytopenic purpura. There has been increasing focus on the interaction between the intestinal microbiome, obesity, and cardiometabolic diseases, and we explore these relationships and the potential roles of different microbial strains. We might someday be able to mine for intestinal bacterial strains that can be used in the diagnosis or treatment of these diseases.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDI; Clostridium difficile infection; FMT; Fecal Transplantation; Gutmicrobiota; Human Disease; IBD; NAFLD; NASH; SCFA; Therapy; UC; fecal microbiota transplantation; inflammatory bowel disease; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; short-chain fatty acid; ulcerative colitis

Mesh:

Year:  2013        PMID: 24018052     DOI: 10.1053/j.gastro.2013.08.058

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  181 in total

1.  Editorial on "Cancer and the microbiota" published in Science.

Authors:  Alison K Hamm; Tiffany L Weir
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

Review 3.  Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns.

Authors:  E G Pamer
Journal:  Mucosal Immunol       Date:  2014-01-08       Impact factor: 7.313

Review 4.  Indole compounds may be promising medicines for ulcerative colitis.

Authors:  Shinya Sugimoto; Makoto Naganuma; Takanori Kanai
Journal:  J Gastroenterol       Date:  2016-05-09       Impact factor: 7.527

Review 5.  Probiotics and necrotizing enterocolitis.

Authors:  Josef Neu
Journal:  Clin Perinatol       Date:  2014-09-30       Impact factor: 3.430

6.  Fecal Microbiota Transplant for Clostridium difficile Colitis-Induced Toxic Megacolon.

Authors:  S P Costello; A Chung; J M Andrews; R J Fraser
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

7.  Capsulized faecal microbiota transplantation ameliorates post-weaning diarrhoea by modulating the gut microbiota in piglets.

Authors:  Wenjie Tang; Daiwen Chen; Bing Yu; Jun He; Zhiqing Huang; Ping Zheng; Xiangbing Mao; Yuheng Luo; Junqiu Luo; Quyuan Wang; Huifen Wang; Jie Yu
Journal:  Vet Res       Date:  2020-04-16       Impact factor: 3.683

Review 8.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 9.  Reconceptualizing anorexia nervosa.

Authors:  Cynthia M Bulik; Rachael Flatt; Afrouz Abbaspour; Ian Carroll
Journal:  Psychiatry Clin Neurosci       Date:  2019-07-01       Impact factor: 5.188

Review 10.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.